Treatment of headache by injection of neuroinhibitory substance to sphenopalatine ganglion or otic ganglion

US2015306188A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2015306188-A1
Application numberUS-201314426303-A
CountryUS
Kind codeA1
Filing dateSep 6, 2013
Priority dateSep 6, 2012
Publication dateOct 29, 2015
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A neuroinhibitory substance for use in a method for treating or preventing headache comprising injecting a neuroinhibitory substance such as botulinium toxin in close proximity to the sphenopalatine ganglion or otic ganglion wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically and the neuroinhibitory substance injected in close proximity to the SPG or OG.

First claim

Opening claim text (preview).

1 . A method comprising injecting a neuroinhibitory substance in close proximity to the sphenopalatine ganglion (“SPG”) or otic ganglion (“OG”), wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically, and the neuroinhibitory substance is injected in close proximity to the SPG or OG. 2 . (canceled) 3 . The method of claim 1 , wherein the neuroinhibitory substance is injected in close proximity to the SPG. 4 . The method of claim 1 , wherein the injection device defines a straight line from skin/mucosa penetration to a point close to the SPG and OG where neuroinhibitory substance release occurs. 5 . The method of claim 3 , wherein the SPG is targeted infrazygomatically. 6 . The method of claim 1 , wherein the substance is injected within 5 mm of the SPG or OG. 7 . The method of claim 1 , wherein the neuroinhibitory substance is botulinum toxin, tetanus neurotoxin, staphylococcal alpha-toxin or acylpolyamine toxin. 8 . The method of claim 1 , wherein said injection device comprises: an end piece for insertion into body tissues at a distal end thereof, the end piece including a rigid lumen for holding an instrument and guiding the instrument to the distal end of the end piece; and a body section supporting the lumen and being rigidly connected thereto, the body section including a navigation array for guidance of the device using a surgical navigation system and/or including an anchor point for a standard navigation array. 9 . The method of claim 8 , wherein the distal end of the end piece comprises a tip for piercing body tissues, the tip having a tapered profile narrowing toward a point. 10 . The method of claim 9 , wherein the tip is adapted to bend the instrument away from a longitudinal axis of the end piece as the instrument is pushed through the lumen and out of the tip. 11 . The method of claim 8 , wherein the end piece comprises a scale or other marking to show the depth of insertion of the end piece into body tissues. 12 . The method of claim 8 , wherein the lumen is rigid enough to permit placement of a tip of the end piece with millimeter accuracy without deformation as the lumen penetrates body tissues and whilst being subject to bending moments that might arise as it is maneuvered along the selected approach toward a target site. 13 . The method of claim 12 , wherein the rigidity of the lumen is sufficient to enable the tip to be placed with millimeter accuracy at the sphenopalatine ganglion (“SPG”) when targeted via a infrazygomatic approach. 14 . The method of claim 8 , wherein the lumen has a rigidity sufficient to limit deflection of a needle as it advances toward the SPG along the lateral approach to a maximum of 2 mm per 10 cm of length of the lumen. 15 . The method of claim 8 , wherein the navigation array is rigidly connected to the body section, the array comprising a plurality of optical or electromagnetic markers located in plane with one another and at known locations relative to the end piece. 16 . The method of claim 8 , wherein the injection device comprises a proximal piece for holding a proximal end of the instrument, the proximal piece being positioned at a proximal end of the end piece and being connected to the end piece either directly or via the body section. 17 . The method of claim 16 , wherein the proximal piece comprises one or more clamp(s) for attachment of the instrument, the clamp or clamps being for fixing the instrument in place relative to the end piece and the distal end thereof. 18 . The method of claim 16 , wherein the proximal piece comprises moveable parts for connection to the instrument and for movement with the instrument as it moves relative to the end piece. 19 . The method of claim 15 , wherein the navigation array is held in a track on the body section that permits slidable movement relative to the body section, and wherein the navigation array is rigidly connected to the instrument via a coupling between the proximal piece and the navigation array. 20 . The method of claim 8 , wherein the end piece is for receiving and guiding a needle. 21 . The method of claim 8 , wherein the lumen is sized to receive a needle of 25G or smaller. 22 . The method of claim 8 , wherein the instrument comprises a needle, the needle including a needle tip having a slightly rounded end and openings on each side of the tip rather than at the tip end. 23 . The method of claim 22 , wherein the injection device comprises a proximal piece for holding a proximal end of the instrument, the proximal piece being positioned at a proximal end of the end piece and being connected to the end piece either directly or via the body section, and wherein a vessel is attached to the needle at the body section or the proximal piece. 24 . The method of claim 23 , wherein the injection device comprises a first, locking, mechanism to lock the proximal piece and a second, injection, mechanism to aspirate and then inject a substance from the vessel. 25 . The method of claim 1 wherein the device is guided to a position in close proximity to the SPG or OG using surgical navigation. 26 . A method comprising treating or preventing headache in a patient in nee thereof, wherein the treatment or prevention comprises injecting a neuroinhibitory substance in close proximity to the sphenopalatine ganglion or otic ganglion, wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion (“SPG”) or otic ganglion (“BOG”) by inserting said injection device into the patient transnasally or infrazygomatically, and the neuroinhibitory substance injected in close proximity to the SPG or OG. 27 . A method comprising treating or preventing rhinitis, rhinosinusitis, Frey syndrome or hypersecretion of tears in a patient in need thereof, wherein the treatment or prevention comprises injecting a neuroinhibitory substance in close proximity to the sphenopalatine ganglion or otic ganglion, wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically, and the neuroinhibitory substance injected in close proximity to the SPG (“SPG”) or OG (“OG”). 28 . (canceled)

Assignees

Inventors

Classifications

  • Botulinum neurotoxin (3.4.24.69) · CPC title

  • Needle locating or guiding means · CPC title

  • Details of monitor hardware · CPC title

  • Electromagnetic tracking systems · CPC title

  • Biopsy devices with actuators, e.g. with triggered spring mechanisms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2015306188A1 cover?
A neuroinhibitory substance for use in a method for treating or preventing headache comprising injecting a neuroinhibitory substance such as botulinium toxin in close proximity to the sphenopalatine ganglion or otic ganglion wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said inje…
Who is the assignee on this patent?
Norwegian Univ Sci & Tech Ntnu
What technology area does this patent fall under?
Primary CPC classification A61K38/4893. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Oct 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).